AXSM - Latest News
Axsome Therapeutics, Inc. (AXSM), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $12.11B. Beta to the broader market is 0.58.
The article list below shows the most recent AXSM headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent AXSM Headlines
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer's Agitation Launch
marketbeat.com - May 12, 2026
Axsome Therapeutics NASDAQ: AXSM executives said the company is preparing for a June launch of AUVELITY in Alzheimer's disease agitation while continu
Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
seekingalpha.com - May 12, 2026
Axsome Therapeutics, Inc.
3 Stocks Poised to Disrupt the Healthcare Market by 2030
fool.com - May 8, 2026
The old healthcare model is breaking down.
Axsome Therapeutics Recognizes Mental Health Month
globenewswire.com - May 7, 2026
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment o
AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales
zacks.com - May 5, 2026
Axsome posts a wider Q1 loss but revenues jump 57%, driven by strong Auvelity and Sunosi sales.
How News Affects AXSM Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track AXSM's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked AXSM news questions
- What is the latest AXSM news headline?
- The most recent AXSM headline (May 12, 2026) is "Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer's Agitation Launch". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the AXSM news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What AXSM news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual AXSM options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.